Seeking Alpha

Keryx Biopharmaceuticals (KERX +4.2%) is trading higher after saying an article on phase 2...

Keryx Biopharmaceuticals (KERX +4.2%) is trading higher after saying an article on phase 2 activity of its drug KRX-0401 has been selected for publication in the October 3 online edition of the Journal of Clinical Oncology. The drug is used to treat patients with refractory, advanced colorectal cancer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|